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Twenty-five dogs were included in a randomized, double- 
blind trial to assess the efficacy of doxycycline (DOX) orally 
administered twice a day at 4 mg/kg/day (n = 12) for the 
treatment of osteoarthritis of the hip. Chondroitin sulfate 
(CS; 525 mg/day) was used as a positive control (n = 13). 
Dogs were re-examined monthly for 6 months after initiation 
of  treatment.  The  assessment  protocol  included  clinical 
score,  radiographic  findings  and  serum  osteoarthritis 
biomarkers. Dogs treated with DOX showed statistically 
significant  improvements  (p  ＜  0.05)  in  lameness,  joint 
mobility,  pain  on  palpation,  weight-bearing  and  overall 
score at 2, 6, 4, 4 and 4 months, respectively, after treatment. 
Biomarker levels of CS-WF6 epitope and hyaluronan were 
significantly increased and decreased (p ＜ 0.05) at 2 and 3 
months after treatment compared to pretreatment. These 
results showed that DOX had a positive therapeutic effect in 
dogs with osteoarthritis.
Keywords: biomarkers, canine, chondroitin sulfate, doxycycline, 
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Introduction 
Osteoarthritis (OA) is a chronic, disabling condition for 
which there are no cure and few useful treatments [9]. 
Clinical features include joint pain, instability, limitation 
of motion and function impairment. The pathogenesis of 
OA, albeit not yet well understood, is often linked to joint 
injury, biochemical alterations and ageing [20]. Pharmacological 
treatment alternatives for OA can be divided into two 
groups: symptom-modifying and disease-modifying drugs 
[7]. Symptom-modifying drugs are at present the prescription 
of choice for patients with OA. Drugs in this group are 
analgesics and non-steroidal anti-inflammatory drugs, 
which are effective in relieving the symptoms of OA [8]. 
There has recently been a lot of debate about some 
biological agents that are thought to have both symptom- 
modifying and disease-modifying properties [8,11].
Most of the compounds suggested as disease- modifying 
drugs are physiological molecules contained in articular 
tissues such as glucosamine sulfate and chondroitin sulfate 
(CS) [13]. A tetracycline antibiotic, doxycycline (DOX), 
has been successfully used to treat a wide-range of bacterial 
infections. In addition to its effects as an antibiotic, laboratory 
studies with animals and with human tissue have shown that 
doxycycline can inhibit the degradation of cartilage in a way 
that could be useful for the treatment of OA [24-26,38]. DOX, 
reportedly limits cartilage degradation and significantly 
ameliorates the degenerative changes that occur in OA 
joints [24-26,38]. Specifically, DOX orally administered at 
low dosages appeared to reduce the rate and extent of joint 
pathology in a canine model of OA [19,36,37]. However, 
most of the papers published about DOX and joint 
pathology were done in vitro [1,2,25,38]. Therefore, this 
study aims to investigate whether the long- term use of DOX 
can favorably modify the progression of OA in dogs. 
Moreover, to confirm preclinical data suggesting that DOX 
can slow the progression of OA. The experimental design 
was developed according to potential clinical use, with 
clinical score, radiographic findings and serum osteoarthritis 
biomarkers as primary outcome measures. 
Materials and Methods
Animals
Twenty-five client-owned dogs were included in this 
study, 12 males and 13 females aged between 1∼7 (4.21 ± 
1.63) years old. Twenty dogs were Golden retrievers and 5 240    Korakot Nganvongpanit et al.
Table 2. Radiographic scoring system for assessing dogs with 
osteoarthritis
Grade Radiographic evaluation
   0 Normal Not affected
   1 Mild Doubtful narrowing of joint space and 
    possible osteophytic lipping
   2 Moderate Definite osteophytes and possible 
    narrowing of joint space
   3 Severe Moderate multiple osteophytes, definite 
    narrowing of joints space, some sclerosis and 
    possible deformity of bone contour
   4 Very severe Large osteophytes, marked narrowing of 
   joint space, severe sclerosis and definite 
   deformity of bone contour
Table 1. Clinical scoring system for assessing dogs with osteoarthritis
Criterion Grade Clinical evaluation
Lameness 1 Walk normally
2 Slightly lame when walking
3 Moderately lame when walking
4 Severely lame when walking
5 Reluctant to rise and will not 
 walk more than five paces
Joint mobility 1 Full range of motion
2 Mild limitation (10∼20%) in 
 range of motion; no crepitus
3 Mild limitation (10∼20%) in 
 range of motion; crepitus
4 Moderate limitation (20∼50%) in 
 range of motion; ± crepitus
5 Severe limitation (＞50%) in 
 range of motion; ± crepitus
Pain on  1 None
 palpation 2 Mild signs; dog turns head 
 in recognition
3 Moderate signs; dog pulls limb away
4 Severe signs; dog vocalizes or 
 becomes aggressive
5 Dog will not allow palpation
Weight bearing 1 Equal on all limbs standing and walking
2 Normal standing; favors affected limb 
 when walking
3 Partial weight-bearing standing and walking
4 Partial weight-bearing standing; 
 non-weight-bearing walking
5 Non-weight-bearing standing and walking
Overall score   1 Not affected
 of clinical  2 Mildly affected
 condition 3 Moderately affected
4 Severely affected
5 Very severely affected
dogs were Labrador retrievers. Informed owner consent 
was obtained and the trial protocol was approved by the 
Faculty of Veterinary Medicine, Chiang Mai University’s 
Ethics Committee, Chiang Mai, Thailand. 
Inclusion/exclusion criteria
Golden and Labrador retriever dogs with clinical signs of 
chronic lameness, stiffness and joint pain and radiological 
evidence of OA of the hip were considered eligible for this 
study. Animals which were pregnant, receiving medication, 
or had hepatic, cardiovascular, gastrointestinal and 
neurological disease, were excluded. Dogs with lameness 
due to lumbosacral instability, infection, immune disease 
and fractures and dogs which previously received drug or 
dietary supplement for OA treatment were also excluded.
Pretreatment evaluation
Dogs were clinically examined and blood samples were 
collected for baseline hematology, blood chemistry and 
biomarker for OA. Radiographs of hip joints were 
interpreted by two veterinarians.
Treatment protocol
The dogs were randomly assigned to two treatment 
groups. The first group (DOX group) received doxycycline 
(2 mg/kg body weight twice daily; Osoth Inter Laboratories, 
Thailand) [19], the second group (CS group) served as 
control group and received chondroitin sulfate (Fortiflex, 
525 mg/dog daily; Virbac, USA). Animal were re-assessed 
monthly for clinical evaluation and blood collection, while 
radiographs were taken every 2 months. Treatment was 
stopped on the end of the 6th month. 
Assessment protocol
Two veterinarians recorded the severity of the clinical 
signs at each monthly visit using an ordinal scoring system 
(Table 1) [10] and all veterinarians scored blind to the 
group classification. The radiographs of hip joints were 
taken every 2 months (3 times per animal) and were 
interpreted by the 2 veterinarians using the Takahashi 
scoring system (Table 2) [28]. Three milliliters of blood 
was collected monthly from the cephalic vein to assess the 
levels of OA biomarkers [16,17,22,23].
Clinical score 
Efficacy of the treatment was determined by the mean of 
a clinical scoring system [10] that assessed the animal 
specific lameness, joint mobility, pain on palpation, 
weight-bearing and overall score of clinical condition. The 
dogs had to walk and trot 6 meters 3 times for the evaluation The effect of doxycycline for canine osteoarthritis treatment    241
Table 3. Sex, age and body weight distribution for all 25 dogs 
which completed the trial
Group Total
Gender
Age (months) Weight (kg)
 Male   Female
Doxycycline 12 5 7 52.25 ± 20.25 30.17 ± 5.13
Chondroitin  13 7 6 49.33 ± 19.58 28.42 ± 5.28
 sulfate
Age and weight data are expressed as mean ± SD; neither were 
significantly different between the two groups (p ＞ 0.05).
Table 4. Comparison of pre-treatment clinical and radiographic 
scores for doxycycline (DOX) and chondroitin sulfate (CS) groups
Parameter
Group
p-value
DOX CS
Lameness 3.92 ± 0.76 3.67 ± 0.89 0.44
Joint mobility 3.08 ± 0.86 3.00 ± 0.60 0.80
Pain on palpation 2.31 ± 0.48 2.33 ± 0.49 0.90
Weight bearing 3.69 ± 0.75 3.67 ± 0.78 0.93
Overall score 3.46 ± 0.78 3.58 ± 0.90 0.72
Radiography score 2.46 ± 0.66 2.67 ± 0.78 0.48
The data are expressed as mean ± SD which were not significantly 
different between two group.
of lameness by 2 veterinarians, following palpation on hip 
joint for joint mobility and pain evaluation. The palpation 
was performed by 2 veterinarians, 30 min apart. 
Radiographs 
Structural joint changes were assessed on serial radiographs 
performed according to the standardized technique 
recommended by Takahashi [28]. Radiographs were taken 
for each animal at enrollment and at 3 and 6 months after 
treatment by the same technician using a usual X-ray 
machine (Kelex, Thailand). Ventrodorsal radiographs 
were obtained with the dog’s hip and the leg in full 
extension position. Repositioning of the dog for subsequent 
radiographs were guided by the original film and the same 
radiographic setting (i.e. kilovolts, milliamperes and 
milliseconds) were used. All radiographs in a dog set (3 
films) were interpreted for all evaluations concomitantly 
by 2 veterinarians using the criteria in Table 2. 
Hematology and biochemistry
Blood samples were analyzed for complete blood counts, 
including hematocrit, hemoglobin level, red blood cell 
count and white blood cell count and the platelet count. 
Two mililiters of serum were analyzed for aspartate 
aminotransferase, alanine aminotranferase, blood urea 
nitrogen and creatinine.
Biomarker assay
The biomarker assays were enzyme-linked immunoassays 
(ELISA) as previously described [16-18,22,23]. This study 
used 2 biomarkers; CS-WF6 epitope and hyaluronan (HA). 
Competitive immunoassay using monoclonal antibody 
WF6
A mouse monoclonal antibody WF6 was raised against a 
shark cartilage aggrecan preparation and a quantitative 
ELISA for the epitope recognized by monoclonal antibody 
WF6 was modified from a previous study [16,22]. The 
antibody was specific for intact CS chains and showed no 
interaction with other sulfated glycosaminoglycans, 
hyaluronan or other polyanions, such as DNA, RNA or 
dextran sulfate. The standard used in the assay was shark 
cartilage aggrecan (A1 fraction) (Sigma-Aldrich, USA) at 
concentrations of 19∼10,000 ng/mL in 6% Bovine serum 
albumin (BSA) in Tris Incubation (TI) buffer (0.1 M Tris 
HCl, pH 7.4 containing 0.15 M sodium chloride, 0.1% 
Tween 20 and 0.1% BSA). Diluted human serum samples 
(1 : 5 in 6% BSA-TI) were added to 1.5 mL plastic tubes 
containing an equal volume of WF6 (cell culture 
supernatant, 1 : 200 dilution in TI buffer). They were 
incubated at 37
oC for 1 h, and then added to the microtiter 
plate, which was pre-coated with shark aggrecan (A1 
fraction). Non-specific protein binding was blocked with 
BSA. The plates were then incubated at 37°C for 1 h, and 
the wells were then washed and peroxidase-conjugated 
anti-mouse IgM antibody (1 : 2,000) was added (100 mL/ 
well; in TI buffer). The bound conjugate was detected by 
adding ortho-phenylenediamine (o-PD) substrate (100 
mL/well in 0.05 M citrate buffer, pH 5.0). The reaction was 
stopped after 10 min with 50 mL/well of 4 M sulfuric acid, 
and absorbance was determined using a microplate reader 
(Titertek multiscan Mcc/340; ICN-Flow, USA) at 492/690 
nm. The concentration of WF6 epitope in supernatant 
samples was calculated by reference to a standard curve.
ELISA-based assay for HA using biotinylated HA- 
binding proteins (HABPs)
Human serum samples or standard HA (HealonR; 
Pharmacia Pharmaceutical AB, Sweden) at various 
concentrations [19∼10,000 ng/mL in 6% bovine serum 
albumin (BSA)-phosphate buffer saline (PBS) pH 7.4] 
were added to 1.5 mL plastic tubes containing biotinylated 
HABPs prepared as described above (1 : 200 in 0.05 M 
Tris-HCl buffer, pH 8.6). The tubes were incubated at room 
temperature for 1 h, and then samples were added to the 
microplate, which was precoated with umbilical cord HA 
(100 mL/well of 10 mg/mL) and blocked with 1% BSA 242    Korakot Nganvongpanit et al.
Fig. 1. Mean scores for lameness, joint mobility, pain on palpation, weight bearing and overall. Black = DOX group; white = CS group.
*Values were significantly different compare to month 0 within the groups (p ＜ 0.05). †Values were significantly different between 
groups within the month (p ＜ 0.05). 
(150 mL/well). The plate was then incubated at room 
temperature for 1 h. The wells were then washed and 
peroxidase-conjugated antibiotin antibody (1 : 2,000 
dilution; Zymed, USA), 100 mL/well in PBS, was added. 
The plate was incubated at room temperature for another 
hour. The detection of conjugated antibody was with o-PD 
substrate and plate reading was carried out as described 
above. The concentration of HA in samples was calculated 
from the standard curve [16,23].
Data collection and statistics
The results of CS and HA analyses are presented as mean ± 
SD. The non-parametric 2-sample Mann-Whitney procedure 
was used to test for differences between the DOX and CS 
groups. The radiograph and clinical sign scores were 
calculated as mean ± SD. The non-parametric 2-sample The effect of doxycycline for canine osteoarthritis treatment    243
Fig. 2. Mean radiography scores. Black  = DOX group; white  = 
CS group. Vertical bar means a standard deviation. 
Fig. 3. Mean of relative change (%) of serum CS-WF6 epitope and hyaluronan (HA). Black = DOX group; white = CS group. *Values
were significantly different compare to month 0 within the groups (p ＜ 0.05). 
†Values were significantly different between groups 
within the month (p ＜ 0.05). 
Mann-Whitney procedure was used to test for differences 
between the DOX and CS groups in the same month and 
between before and after treatment. The relative data was 
analyzed using the Statistical Analysis System version 8.0 
(SAS Institute, USA) software package. p ≤ 0.05 was 
considered to be significant.
Results
Thirty dogs were enrolled in the trial but 5 were 
withdrawn due the failure to attend an assessment 
appointment (2 dogs in the DOX group, 1 in the CS group) 
and death from a car accident (1 dog in the DOX group and 
1 in the CS group). Table 3 shows the summary of age, sex 
and body weight data of 25 dogs completing the trial to the 
6th month. All dogs enrolled in the trial had hemogram and 
biochemical profile results within reference range throughout 
the trial (6 months). Comparisons of pre-treatment disease 
score found no significant difference (p ＞ 0.05) between 
the DOX and CS groups (Table 4). 
Fig. 1 presents the 5 clinical score data before treatment 
(month 0) and at one month intervals until 6 months. The 
lameness score in the DOX group showed significant 
improvements (p ＜ 0.05) at th..e 2nd month, while in the 
CS group it showed significant improvements (p ＜ 0.05) 
in the first month. Joint mobility score in the DOX and CS 
groups showed significant improvements (p ＜ 0.05) at the 
6th and 4th months, respectively. Pain at palpation, weight 
bearing and the overall score in the DOX group showed 
significant improvements (p ＜ 0.05) at the 4th month, but 
in the CS group it showed significant improvements (p ＜ 
0.05) earlier, in the 2nd month of treatment. Lameness, 
joint mobility, pain of palpation and overall score in the CS 
group was significant better (p ＞ 0.05) than in the DOX 
group. The weight bearing score in the CS group was 
significant better (p ＞ 0.05) than in the DOX group from 
the first month.
Radiography scores are shown in Fig. 2. Those scores 
were not significantly difference between treatment groups 
(p ＞ 0.05). When comparing with the pretreatment scores, 
there also was no significant difference (p < 0.05).
The results of serum biomarkers for OA are shown in Fig. 
3. The level of CS-WF6 epitope in the DOX and CS groups 
were significantly higher than before treatment. Differences 
between the 2 groups were significant in the first and 
second months after treatment. The level of HA in the 
DOX and CS groups were significantly higher than before 
treatment after 3 and 1 months of treatment, respectively.
Discussion
The results of this study showed that dogs with OA had 244    Korakot Nganvongpanit et al.
significant improvements in score for clinical evaluation 
and biomarker levels when treated with oral DOX. 
However, all of these effects occurred slower when 
compared to CS. 
Disease-modifying or symptomatic slow-acting drugs are 
more interesting because some have been shown to be 
effective in improving symptoms and in reducing OA 
cartilage degradation with a reasonable safety profile 
[8,11]. These drugs have shown onset of efficacy and a 
prolonged residual effect once treatment is stopped [7]. As 
this study was a clinical trial, CS was chosen as positive 
control in order to address ethical responsibilities and the 
welfare of the participant dogs. According to previous 
studies, CS has been shown to reduce pro-inflammatory 
factors, modify the cellular death process and improve the 
anabolism/catabolism balance of extracellular cartilage 
matrix [12,13]. At the same time it has proven to have a 
positive effect on the pathological process involving the 
synovial tissue and subchondral bone. These mechanisms 
could, account for the beneficial results observed in some 
clinical trials [12,13,31]. 
The recognized limitation of this study was the lack of an 
objective assessment of the joint. It was not possible to 
perform ground force reaction measurements as was done 
in the trials of Hazewinkel [6], Moreau [14] and Vasseur 
[32] as this was a multicenter trial. Subjective assessment 
of weight bearing by 2 blinded veterinarians was used 
instead. Our study found that DOX had a slower effect on 
clinical improvements compare to CS. The overall score 
was improved 3 months after treatment, while CS had a 
significant effect 2 months after treatment. Moreover, we 
found that DOX did not improve the measures of pain as 
well as CS. Radiographic findings did not show any 
significant changes. In agreement with a published study 
[4], DOX did not significantly prevent the onset of 
progressive joint space narrowing (JSN) in the contralateral 
knee, and did not improve measures of pain or function of 
the OA knee.
The morphological changes in OA include alterations in 
the cartilage, subchondral bone, and synovial membrane 
[9,20]. Current knowledge points to an important 
involvement of the matrix metalloproteases (MMPs) class 
in the OA process [20]. Collagenase-3 (MMP-13) was 
demonstrated to play a major role in cartilage degeneration. 
It is also suggested that another enzyme, aggrecanase-2, or 
ADAMTS-5 plays a predominant role in the proteolysis of 
OA cartilage aggrecan [5,27].
It is recognized that MMPs play a role in the pathologic 
breakdown of the joint extracellular matrix in OA. It is 
known that low-dose regimens of a tetracycline analogue, 
namely DOX can inhibit some MMPs, hence reducing the 
extracellular matrix breakdown [1,2]. A recent study 
examined the effects of DOX on knee OA progression [4]. 
The primary outcome measure was JSN in the medial 
tibiofemoral compartment. Obese females with a unilateral 
OA knee were randomly assigned to receive 30 months of 
treatment with DOX or placebo. The loss of joint space 
width in the index knee in the DOX group was less than in 
the placebo group. This study showed that DOX can reduce 
the progression of established OA in this patient 
population. It provides the first proof of concept of the 
effectiveness of anti-MMP strategies for developing 
disease-modifying drugs. 
Inhibition of the MMPs superfamily is a very logical 
objective in OA. Moreover, tetracyclines inhibit collagenase 
levels and nitric oxide production in vitro, thereby 
decreasing chondrocyte MMPs activity and increasing 
proteoglycan synthesis attenuating OA in animal models 
[1]. In agreement with a previous study, Pardy [19] showed 
DOX treatment conserved bone strain energy density at 72 
weeks. Doxycycline had little effect on the degradation of 
superficial osseous tissue at 36 week after anterior cruciate 
ligament transection (ACLT); by 72 weeks, DOX in ACLT 
canine model limited subchondral bone loss within the first 
3 mm of periarticular bone with established OA. 
Significant bone loss occurred in the deeper trabecular 
bone for all groups. Substantial architectural adaptation 
within deeper trabecular bone accompanied changes in 
mechanics in early and established OA. In 1991, Yu was 
done in vitro studies, and indicated that levels of neutral 
MMPs in OA cartilage are elevated and that doxycycline 
inhibits collagenolytic and gelatinolytic activity in extracts 
of OA cartilage [38]. However, before tetracycline and its 
analogues, or even MMP inhibitors, can be considered to 
be an effective treatment in preventing knee OA 
progression, further investigations are needed.
A novel monoclonal antibody CS-WF6, which 
recognizes a native epitope in CS chain [23], was elevated 
after treatment. The finding of elevated levels of serum 
CS-WF6 epitope after treated with both DOX and CS 
reflector to alteration the metabolism of the cartilage. In 
chronic OA, the level of CS-WF6 epitope is higher than 
normal because the native CS chain in cartilage was 
degraded and release into the blood system [16,17,23]. The 
elevation of CS-WF6 epitope in this study was shown both 
drugs induced the synthesis of CS-chain in cartilage lead to 
have more proportion of CS in the cartilage. This new CSs 
were source of the degradation process in OA joint which 
made a CS-WF6 epitope up-regulation. We found DOX 
had a slower effect on cartilage metabolism than CS. In this 
study, the level of CS-WF6 epitope was found to be 
significantly elevated after 1 and 2 months in CS and DOX 
groups, respectively.  
In an inflammatory rat model of arthritis, it was 
demonstrated that serum HA levels correlated with the 
degree of synovitis and clinical arthritis [3]. HA plays the 
key role in immobilizing aggrecans in articular cartilage; 
this balances the tension and compressive resilience in the The effect of doxycycline for canine osteoarthritis treatment    245
collagen network by its osmotic properties. Also, the HA 
levels were related to joint inflammation in humans [21]. 
Serum HA has been studied as a biomarker of disease 
progression, since significantly increased levels were 
reported in cases of rheumatoid arthritis and progressive 
osteoarthritis, compared to the normal population 
[3,21,23]. In our study, the HA levels were significantly 
decreased after 1 and 2 months in CS and DOX groups, 
respectively. This means that both DOX and CS decreased 
the level of inflammation in the joint. Compared between 2 
groups, CS reduce inflammation significantly faster than 
DOX. 
The one importance issue in using DOX as disease- 
modifying drug in OA is the microbial resistance. This trial 
did not study the effect of using a chronic, sub-antimicrobial 
dose of DOX on microbial resistance. However, many 
studies had proved that using sub-antimicrobial dose DOX 
(20 mg twice a day) had no effect on the microbial 
resistance [29,35]. Microbial studies have documented 
the lack of any antimicrobial effect on the normal flora, 
periodontal and/or opportunistic pathogens, or change in 
antibiotic susceptibilities following the use of a sub- 
antimicrobial dose of DOX up to 9 months in double- 
blinded, placebo controlled, multicentered studies [29]. 
These studies examined the effect, or lack of effect, of 
sub-antimicrobial dose DOX on the sub-gingival flora 
[29,30,35] and on antibiotic resistances within this flora 
[29] in a periodontitis population. Likewise, there was no 
detectible effect of a 9-month regimen of sub-antimicrobial 
dose of DOX on the intestinal flora of a periodontitis 
population cross-sectionally, relative to placebo control, or 
longitudinally within the sub-antimicrobial dose DOX 
treatment group [33]. In 2007 Walker and colleague [34] 
had reported that there was no evidence that exposure to 
DOX, 20 mg twice a day, resulted in cross- or multiantibiotic 
resistance. No evidence was present that the use of a 
sub-antimicrobial dose of DOX for a period of 24 months 
in a population of periodontally diseased osteopenic 
women exerted any detectible effect on the microbial flora 
as determined by total anaerobic counts and total counts for 
actinomyces and streptococci. There was no evidence that 
a sub-antimicrobial dose of DOX resulted in the 
colonization or overgrowth by periodontal and/or 
opportunistic pathogens. In our trial, we used 4 mg/kg 
DOX daily, which is a sub-antimicrobial dose (10 mg/kg 
daily) [15], related to all publications which mention above 
that possible is using 4 mg/kg DOX daily has no effect on 
the microbial resistance. However, all studies on microbial 
resistance had been done in humans not canine, so to fulfill 
this hypothesis, the sub-antimicrobial dose effect on 
microbial resistance needs to be done in canines in the 
future. 
OA is, by far, the most common type of arthritis in human 
and animals encountered worldwide, yet the development 
of effective disease-modifying treatments has lagged 
behind that of other arthritides. Current challenges that 
need to be met are an ideal pharmacy by using novel 
knowledge of the biochemistry, molecular biology and 
imaging findings that stop progression of disease and 
recovery of the cartilage function.  This study showed one 
of the drugs which can be used as an OA disease-modifying 
drug, even though the efficacy was not as great as the 
positive control. However, comparing the cost-benefit of 
DOX, we believe that DOX will be the disease-modifying 
drugs of choice for treated OA in dogs. Indeed, the results 
of the present study suggest that using DOX 4 mg/kg daily 
for 6 months had no effect on the liver and kidney 
functions. This drug can improve the clinical signs of OA 
in a dog within 4 months. Moreover, we showed orally 
administered DOX can alter the anabolism of the articular 
cartilage. This information may prove useful for using 
DOX as disease-modifying drug in clinical practice.
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